Search

Your search keyword '"Lanreotide -- Forecasts and trends"' showing total 6 results
Start Over Descriptor "Lanreotide -- Forecasts and trends" Journal financial services monitor worldwide
6 results on '"Lanreotide -- Forecasts and trends"'

1. Rapid Growth Projected For Acromegaly Market At A CAGR Of More Than 18% Through 2024-2028 As Per The Business Research Company's Acromegaly Global Market Report 2024

Subjects
Business -- Research, Lanreotide -- Forecasts and trends, Acromegaly -- Forecasts and trends, Company growth, Market trend/market analysis, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - As per The Business Research Companys Acromegaly Global Market Report 2024, the acromegaly market is on a rapid growth trajectory, with substantial increases anticipated in the coming years. [...]

Published
2024

3. Somatostatin Analogs Market Report 2024: Global Trends, Forecast and Competitive Analysis to 2030 - Opportunities in the Acromegaly and Neuroendocrine Tumor Markets

Subjects
Tumors -- Forecasts and trends, Lanreotide -- Forecasts and trends, Somatotropin -- Forecasts and trends, Acromegaly -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - The 'Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2030' report has been added to ResearchAndMarkets.com's offering. The global somatostatin analogs market is expected to reach [...]

Published
2024

4. Amryt Announces Details of EMA Contingent Value Rights Payment

Subjects
Lanreotide -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Amryt Announces Details of EMA Contingent Value Rights Payment DUBLIN, Ireland, and Boston MA, May 17, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, [...]

Published
2022

5. Amryt Announces Successful Bioavailability Study for MycapssaA (octreotide capsules)

Subjects
United States. Food and Drug Administration, Lanreotide -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Mycapssa (Medication)
Abstract

(GlobeNewswire) - Amryt Announces Successful Bioavailability Study for Mycapssa (octreotide capsules) Data supports a planned Phase 3 study in the treatment of carcinoid symptoms associated with Neuroendocrine Tumors (NET) Global [...]

Published
2022

6. Amryt Completes $125 Million Non-Dilutive Debt Refinancing

Subjects
Ares Management Corp. -- Forecasts and trends -- Finance, Investment advisers -- Forecasts and trends, Lanreotide -- Forecasts and trends, Company financing, Market trend/market analysis, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Amryt Completes $125 Million Non-Dilutive Debt Refinancing New Facilities Will Significantly Reduce Amryts Interest Expense and Cost of Capital and Extend Term Debt Maturity Through 2027 Further Strengthens [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results